A Study in Subjects With Late Prodromal & Early Manifest HD to Assess the Safety, Tolerability, pk, and Efficacy of Pepi

ClinicalTrials.gov ID: NCT02481674

Public ClinicalTrials.gov record NCT02481674. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease to Assess the Safety, Tolerability, pk, and Efficacy of Pepinemab

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of Pepinemab in subjects with late prodromal and early manifest Huntington's disease.

Study identification

NCT ID: NCT02481674
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Vaccinex Inc.; Industry
Enrollment: 301 participants

Conditions and interventions

Conditions

Huntington's Disease

Interventions

VX15/2503 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 21 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 2015 (Type not available)
Primary completion: Aug 2020 (Actual)
Completion: Aug 2020 (Actual)
Last update posted: May 2, 2022

2015 – 2020

United States locations

U.S. sites: 29
U.S. states: 21
U.S. cities: 27

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35233	—
University of California, San Diego	La Jolla	California	92037	—
University of California San Francisco	San Francisco	California	94143	—
University of Colorado - Denver	Aurora	Colorado	80045	—
Georgetown University	Washington D.C.	District of Columbia	20007	—
University of Florida Gainesville	Gainesville	Florida	32611	—
Emory University School of Medicine	Atlanta	Georgia	30329	—
Indiana University School of Medicine	Indianapolis	Indiana	46202	—
University of Iowa	Iowa City	Iowa	52242	—
University of Louisville	Louisville	Kentucky	40202	—
Johns Hopkins University	Baltimore	Maryland	21218	—
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Massachusetts General Hospital	Charlestown	Massachusetts	02129	—
University of Michigan	Ann Arbor	Michigan	48105	—
Washington University	St Louis	Missouri	63110	—
Columbia University	New York	New York	10027	—
Columbia University	New York	New York	10032	—
University of Rochester	Rochester	New York	14618	—
Duke University Health Center	Durham	North Carolina	27705	—
Wake Forest University	Winston-Salem	North Carolina	27157	—
University of Cincinnati	Cincinnati	Ohio	45267	—
Ohio State University	Columbus	Ohio	43210	—
University of Toledo	Toledo	Ohio	43614	—
Vanderbilt University	Nashville	Tennessee	37232	—
University of Texas Houston Medical School	Houston	Texas	77030	—
University of Vermont	Burlington	Vermont	05401	—
Virginia Commonwealth University	Richmond	Virginia	23298	—
University of Washington and VA Puget Sound Health Care System	Seattle	Washington	98195	—
University of Washington	Seattle	Washington	98195	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02481674, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 2, 2022 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02481674 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →